← FDA DRUG APPROVALS

FDA ANDA · ANDA090808

HEPARIN SODIUM

Sponsor: SAGENT PHARMS

APPLICATION
ANDA090808
TYPE
ANDA
ORIGINAL APPROVAL
2010-06-30
LATEST ACTION
2020-07-08
ROUTE
INTRAVENOUS, SUBCUTANEOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

HEPARIN SODIUMPrescription
HEPARIN SODIUM 5,000 UNITS/ML · INJECTABLE · INJECTION
HEPARIN SODIUMPrescription
HEPARIN SODIUM 10,000 UNITS/ML · INJECTABLE · INJECTION
HEPARIN SODIUMPrescription
HEPARIN SODIUM 1,000 UNITS/ML · INJECTABLE · INJECTION

Approval history

2020-07-08Labeling · Supplement 25 · standardAP
2014-02-20Labeling · Supplement 10 · standardAP
2013-05-01Labeling · Supplement 9 · standardAP
2013-04-29Labeling · Supplement 5AP
2013-04-29Labeling · Supplement 8 · standardAP
2010-11-24Labeling · Supplement 2AP
2010-06-30OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →